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ABSTRACT 
Arylhydrocarbon receptor (AHR) is a ligand activated transcription factor involved in 
xenobiotic metabolism. Plexiform neurofibromas (PNF) can transform into malignant 
peripheral nerve sheath tumors (MPNSTs) that are resistant to existing therapies. These 
tumours are primarily composed of Schwann cells. In addition to NF1 gene inactivation, 
further genetic lesions are required for malignant transformation. We have quantified the 
mRNAs expression levels of AHR and its associated genes in 38 human samples. We report 
that AHR and the biosynthetic enzymes of its endogenous ligand are overexpressed in human 
biopsies of PNF and MPNST. We also detect a strong nuclear AHR staining in MPNST. The 
inhibition of AHR by siRNA or antagonists, CH-223191 and trimethoxyflavone, induces 
apoptosis in human MPNST cells. Since AHR disregulation is observed in these tumors, we 
investigate AHR involvement in Schwann cell physiology. Hence, we studied the role of 
AHR in myelin structure and myelin genes regulation in Ahr-/- mice during myelin 
development. Ahr ablation leads to locomotion defects and provokes thinner myelin sheaths 
around the axons. We observe a disregulation of myelin genes expression, and myelin 
developmental markers in Ahr-/- mice. Interestingly, AHR does not directly bind to myelin 
gene promoters. The inhibition of AHR in vitro and in vivo increased β-Catenin levels and 
stimulated the binding of β-Catenin on myelin gene promoters. Taken together, our findings 
reveal a new endogenous role of AHR in peripheral myelination, and in peripheral nerve 
sheath tumors. Finally, we suggest a potential therapeutic approach by targeting AHR in 
nerve tumors. 
 
Significance statement 
Aryl hydrocarbon receptor (AHR) is well known to mediate xenobiotic metabolism in 
vertebrates. Growing evidences reveal that AHR seems to have endogenous roles in the 
development and functioning of different organs. In our current study, we describe a novel 
role of AHR in peripheral myelination and in nerve sheath tumours. We show that AHR 
pathway is disregulated in human biopsies of nerve tumours. The blockade of AHR provokes 
cell death in nerve tumours, suggesting a new therapeutic avenue in the treatment of this 
invasive cancer. Furthermore, the inhibition of AHR in mice provokes locomotor defects and 
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alteration of myelin structure. This work unravels a new endogenous role of AHR in 
peripheral myelination and a potential treatment of nerve tumours. 
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INTRODUCTION 
Neurofibromatosis type 1 (NF1, #MIM162200) is an autosomal dominant neuro-cutaneous 
tumor predisposition syndrome caused by germline heterozygous mutation in the NF1 gene (1). 
The most common NF1-associated tumors are benign peripheral nerve sheath tumors called 
neurofibromas which may be dermal or plexiform (2). Dermal neurofibromas are typically small 
and grow as discrete lesions in the dermis whereas plexiform neurofibromas (PNF) can develop 
internally along the plexus of major peripheral nerves and become quite large. PNFs can undergo 
transformation to malignant peripheral nerve sheath tumors (MPNSTs) in about 10% of NF1 
patients (3). MPNSTs are resistant to conventional therapies, and their deep-seated position and 
locally invasive growth hinder complete surgical resection with high degree of relapse rendering 
new treatments highly indispensable. Peripheral nerve Schwann cells (SCs) are the primary 
pathogenic cells in neurofibromas and MPNSTs, as bi-allelic mutation or loss of the NF1 gene 
occurs uniquely in tumor SCs (4). NF1 encodes the RAS-GAP (Rat sarcoma GTPase activating 
protein) neurofibromin, and RAS signaling is elevated in neurofibroma SCs (5). Neurofibromas 
may develop from SCs or Schwann cell progenitors (SCPs) due to the inactivation of Nf1 at the 
SCP stage or in adult mice (6) (7). 
Schwann cells (SC) carry out the myelination of axons in the nerve (8). Myelin is essential for 
rapid action potential propagation along the axons (9). Peripheral myelin genes expression (Myelin 
Protein Zero (P0) and Peripheral Myelin Protein-22 (PMP22)) is tightly regulated in SC (10). 
Krox20 (11), Wnt/β-Catenin signaling pathway (12) are known positive regulators of myelin gene 
expression, whereas Sox2 (13) and LXR (14) exert a negative effect.  
Little is known of the additional cooperating genetic events potentially required for full 
plexiform neurofibroma’s malignant transformation. Previous researches from our laboratory and 
others have shown an activation of the Wnt signaling pathway, during malignant transformation 
of plexiform neurofibromas to MPNSTs (15, 16). Indeed, Wnt pathway is a common conjuncture 
between myelin development as well and malignant transformation. There is a growing evidences 
that over-activation of AHR (aryl hydrocarbon receptor) signaling pathway can alter Wnt/β-
Catenin signaling in development, different human cancers and disease (18, 19). 
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AHR is a ligand-activated transcription factor that is best known for mediating the toxicity and 
tumor-promoting properties of the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
commonly referred to as dioxin. The activation of AHR provokes its heterodimerisation with AHR 
Nuclear Translocator (ARNT). They bind specific responsive elements called Xenobiotic 
responsive elements (XREs), located in the promoter regions of the target genes and consequently, 
leading to their transactivation (e.g. Cytochrome 1A1). Nevertheless, its endogenous functions 
begin to emerge (17) and natural ligands of the AHR, like tryptophan derivatives, were identified. 
The AHR is present in ancient invertebrate organisms like C. elegans, where it is responsible for 
the regulation of GABAergic neuron fate specification (18). Kynurenine is a tryptophan catabolite 
generated via Tryptophan Dioxygenase (TDO) and Indoleamin 2,3-Dioxygenases (IDO). By 
activating AHR, kynurenine promotes tumor-cell survival and malignancy of glioma (19). Despite 
the discovery of the cognate ligand of AHR, the endogenous role of the AHR remains poorly 
explored, especially in the peripheral nervous system. 
In this study, we report an upregulation of AHR signaling in PNF and MPNST. Furthermore, 
the inhibition of AHR promotes MPNST cell apoptosis. On the other hand, we investigate the role 
of AHR in normal Schwann cell physiology and myelin genes regulation using Ahr-/- mice. These 
mice have thinner myelin sheaths, dysregulated myelin genes expression, and consequent 
locomotor deficiencies. Taken together, our results elicit a novel role of the AHR in peripheral 
myelin genes regulation and a stimulation of AHR activity in malignant transformation of 
peripheral nerve sheath tumors. Our results also suggest that targeting AHR could be a promising 
avenue in the treatment of PNF and MPNST. 
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RESULTS 
AHR signaling pathway is activated in peripheral nerve sheath tumorigenesis 
 In a series of 38 tumors, we first analyzed mRNA expression of AHR, AHRR (AHR 
Repressor), and ARNT (Table 1). AHR was significantly up-regulated in plexiform 
neurofibromas (7-fold) and in MPNSTs (9-fold), compared to the dermal neurofibromas. 
AHRR was significantly down-regulated in plexiform neurofibromas (3-fold) and MPNSTs 
(2-fold) compared to the dermal neurofibromas, while ARNT expression was not 
significantly altered in either the plexiform neurofibromas or the MPNSTs. 
 Several genes implicated in AHR pathway were also tested, including kynurenine 
metabolism (IDO1, IDO2, and TDO2), inflammation and immune pathways (IL1ß, IL6, IL8, 
CXCL5, and CXCL6), SC markers (S100B, and P0) and the proliferation (MKI67). IDO1, 
and TDO2 (but not IDO2) were significantly up-regulated in plexiform neurofibromas and 
in MPNSTs. Concerning the inflammatory pathway: IL1ß, IL6, IL8, CXCL5, and CXCL6 
mRNA levels showed significant overexpression in plexiform neurofibromas and in 
MPNSTs, compared to the dermal neurofibromas (Table 1). It is noteworthy that AHR and 
the enzymes of its endogenous ligands are remarkably higher in MPNSTs than in PNFs. The 
proliferation-associated gene MKI67 was overexpressed in the MPNSTs. SC-specific genes 
(S100B, P0) expression was shown to be significantly down-regulated in MPNSTs. 
We also performed an immunostaining of AHR in MPNST (Fig. 1). We detected 
strong nuclear AHR staining in a proportion of tumor cells, while intra-tumoral vessels and 
fibroblasts in a fibrous septum (taken as internal negative controls) were not stained. 
Altogether, our data show that AHR pathway is activated in human PNFs and MPNSTs.  
AHR inhibition induced apoptosis in MPNST cell lines. 
 As we observed AHR pathway is activated in human plexiform neurofibromas and 
MPNSTs. Subsequently, we hypothesized that inhibiting the AHR could affect MPNST cell 
survival. We used two AHR antagonists (CH and TMF) to inhibit AHR activity in STS26T. 
Treatment with CH-223191 (50µM at 48h and 72h) modestly increased cell death and 
enhanced apoptosis and shifted to late apoptotic state (Double positive for both Annexin and 
PI cell population) as quantified by Annexin V and PI staining (Fig.2A: 48 h, and Fig.2B: 72 
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h; Fig.S1A). CH did not have any effect at 10 µM, whereas TMF exhibited a more potent 
effect on MPNST cell death even at 10 µM. TMF (10µM, 48h or 72h) decreased cell viability 
by approximately 50%. After incubation with TMF (10µM, 72h), approximately 20% of the 
cells underwent apoptosis and 30% were late apoptotic. As expected, CH-223191 and TMF 
inhibited the expression of AHR target gene: CYP1A1 (Fig. 2C). To confirm that this is due 
to AHR inhibition, we silenced AHR by siAHR. AHR silencing also induced apoptosis in 
STS26T dose dependently (Fig 2D). Silencing of AHR drastically decreased the mRNA 
levels of AHR and its target genes CYP1A1 and CYP1B1 (Fig. 2E). As the IL1ß expression 
was enhanced in plexiform neurofibromas and MPNSTs (Table 1), accordingly the inhibition 
of AHR either by siRNA or antagonists reduced IL1ß expression in STS26T cells (Fig. 2F). 
 We confirmed these results using another MPNST cell line, 90-8. As expected, CH 
inhibited the expression of the classical AHR target genes: CYP1A1 and CYP1B1 (Fig. S2A). 
Treatment with CH (50µM) increased the number of dead cells (Fig. S2B, SC) and enhanced 
apoptosis. We confirmed this result with siAHR (Fig S2D, S2E). Furthermore, it also reduced 
the expression of IL1ß (Fig. S2G).  
Ahr ablation in mice caused locomotor defects and led to thinner myelin sheath. 
Given the fact that PNF and MPNST is a complex tumor with different cells, we analyzed 
the expression of AHR and related components in different cells like Schwann cells, mast 
cells and endothelial cells. AHR mRNA is predominant in Schwann cells and may suggest 
its importance in Schwann cells physiology (Table 2). The observed activation of AHR 
pathway and the down-regulation of myelin gene (P0) and as well as S100B in plexiform 
neurofibromas and MPNSTs compelled us to investigate further the role of AHR in normal 
Schwann cells. Henceforth, we analyzed AHR expression in sciatic nerves and Schwann 
cells (Fig. 3A - C). AHR is expressed in the nerve (Fig.3A, C) and is localized in the nucleus 
of SC as well as the perinuclear compartment (Fig. 3B).  
We analyzed the locomotor behavior of Ahr-/-. We measured stride time using a motorized 
treadmill (Fig. 3D). No significant difference was observed with treadmill speed at 10 cm/s. 
However, when treadmill speed was increased at 16 cm/s, Ahr-/- mice showed slower stride 
than WT. At higher speed, Ahr-/- mice were not able to maintain the rhythm and therefore 
could not be tested. 
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Mice were then subjected to fixed speed rotarod protocol (14 rpm) for five consecutive days 
where the time to withstand the rotating rod was measured (Fig. 3E). The WT mice 
significantly improved their performance over days indicating an amelioration of their motor 
coordination, whereas the time latency of Ahr-/- mice remained constant. Indeed, WT mice 
were able to stay on the rotating bar on day 5 while Ahr-/- mice remained only. Our findings 
suggest that the Ahr-/- have impaired locomotion and motor coordination. Then, we 
performed the static rod test (Fig. 3G). All WT mice stayed 100s on the bar. In contrast, Ahr-
/- mice were unsuccessful in staying (Fig. 3H). Finally, motor performance was evaluated 
using a dynamic rod test. The Ahr-/- mice were 3-times slower than the WT mice in crossing 
the rod (Fig. 3I). The Ahr-/- mice also exhibited more faults while crossing the rod (Fig 3I).  
We studied myelin structure by electron microscopy. The myelin sheath of Ahr-/- mice was 
significantly thinner than controls (Fig.3J, 3K) and the axonal perimeter was higher in Ahr-/- 
mice compared to controls (Fig.3L). We plotted the g-ratios of sciatic nerve fibers as a 
function of their respective axonal perimeters (Fig.3M). We observed reduction in myelin 
thickness for all axon calibers, but smaller axons were more affected.  
Western blot showed significant increase of P0 and PMP22 in Ahr-/- sciatic nerves (Fig.3N). 
Consistent with these results, the expression of the negative regulator of myelination, Sox2, 
was reduced by 40% in Ahr-/- mice (Fig.3N), while the expression of active β-Catenin was 
enhanced by 2-fold and total β-Catenin was decreased by 40%. Therefore, the ratio active β-
Catenin over total β-Catenin is increased by 3.5-fold in in Ahr-/- mice suggesting an activation 
of the Wnt/β-Catenin pathway.  
Ahr is involved in myelination during development 
To determine when these myelin abnormalities arose, we analyzed the expression 
pattern of AHR during the myelination process at P7, P21 and in 8-weeks old mice and 
compared it to the expression of positive modulators of myelination process: Krox20 and β-
Catenin. As depicted in figure 4A, AHR expression was at the highest level at P7 and then 
decreased at later time points to reach its lowest level in adult mice. Krox20 expression 
gradually increased during the myelination process to attain the highest level at P21 and, as 
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expected, dropped in adult animals. Finally, β-Catenin increased at P21, and then its 
expression was brought back to the same levels of P7 and at 8WO.  
Taking account of this difference in AHR expression during development, we 
analyzed structure of myelin sheaths from sciatic nerves of P7 mice (Fig. 4B). We observed 
a mild disorganization of myelin sheaths in Ahr-/- mice without affecting the g-ratio (Fig. 4C) 
or axonal perimeter (Fig.4D). Nevertheless, Ahr-/- mice displayed fewer myelinated axons 
(28.88±1.18 for WT vs 20.88±1.23 for Ahr-/-, Fig.4E).  P0 (-50%) and PMP22 (-60%) protein 
expression was decreased in 7-days-old Ahr-/- mice (Fig.4F). To explore if myelin gene 
inhibition is due to a dysregulation in the expression of the major transcriptional regulators 
of SC myelination, we quantified the expression of Sox2, Krox20, total β-Catenin and active 
β-Catenin. The knockout of Ahr did not affect the expression of Sox2. However, we observed 
a decreased Krox20 expression (-60%) that was confirmed by IHC experiments. We 
observed a 25% reduction of the number of Krox20 positive cells in the sciatic nerves as 
suggested by DAPI staining (Fig.4G). Furthermore, WB analyses showed that active β-
Catenin expression was diminished by 30% in Ahr-/- nerves (Fig. 4F). As the amount of total 
β-Catenin is increased in Ahr-/- mice (+35%), we observed a decrease of the ratio of active 
β-Catenin over total β-Catenin suggesting an impairment of the Wnt/β-Catenin pathway at 
P7 when Ahr is knocked out. At P21, electron microscopy images revealed that myelin 
sheaths are affected by the deletion of Ahr (Fig. 4H). The g-ratio was decreased designating 
thicker myelin sheaths around the axons of Ahr-/- mice (Fig. 4I). The axonal perimeter was 
reduced (Fig. 4J) while the numbers of myelinated were not affected in Ahr-/- mice (Fig. 4K). 
At P21, P0 and PMP22 expression were stimulated by 2-fold in Ahr-/- mice. Sox2 expression 
was not still affected, while the expression of all the positive regulators was activated in Ahr-
/- mice: Krox20 (+50%), total β-Catenin (+60%) and active β-Catenin (+35%) (Fig. 4L). 
Altogether, our data point-out a crucial and differential role of Ahr during myelination 
process and highlight that Ahr knockout leads to defects in myelin sheaths. 
AHR regulates myelin gene expression in Schwann Cells 
We transfected MSC80 cells with either non-targeting siRNA (NT) or siAhr. First, 
the efficacy of the knock-down was evaluated by RT-qPCR (Fig. S3A) and western blot (Fig. 
S3B). In addition, we assessed the functional efficacy of the siAhr on Cyp1A1- Luciferase 
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activity that was reduced drastically (-80%) (Fig. S3C). The knock-down of Ahr increased 
mRNA levels of P0 and PMP22 by 50% (Fig. 5A) and the promoter activity of P0 as well as 
PMP22 (Fig 5B). Taken together, the silencing of Ahr in SC line or its knockout in mice led 
to a disregulation of myelin gene expression. 
Then, we examined the mechanism by which the AHR regulates myelin gene 
expression. We identified by MatInspector software four potential binding sites for AHR on 
the level of P0 promoter and one putative AHR binding site on Pmp22 promoter (Fig. 5C). 
Therefore, we tested the AHR binding on P0 and Pmp22 promoters by ChIP. As a positive 
control, we assayed the binding of the AHR on the level of its target gene: Cyp1A1 promoter. 
As expected the AHR bound to Cyp1A1 promoter (Fig. 5D). This binding was enhanced by 
2-fold after treatment with TCDD (100nM; 1h). However, we did not detect AHR interaction 
with any of the putative binding sites identified on Pmp22 (Fig. 5E) and P0 (Fig. 5F), even 
after the incubation of MSC80 with TCDD (loading control: Fig. S4A). These data showed 
that AHR does not seem to interact directly with myelin gene promoters. 
 The other possible mechanism of action of AHR is the cross-talk with another 
signaling pathway. We previously showed that activated Wnt/β-Catenin pathway enhances 
the expression of peripheral myelin genes (12). Furthermore, we demonstrated that the 
knocking-out Ahr in mice altered β-Catenin expression in the sciatic nerve (Fig. 3N). 
Therefore, we addressed the question whether the action of AHR is mediated by Wnt/β-
Catenin pathway. After silencing Ahr in MSC80 cells, we observed a 50% increase in the 
protein levels of active β-Catenin and a 30% increase of total β-Catenin levels (Fig. 5G). 
Furthermore, to support the hypothesis, knock down of Ahr led to a significant stimulation 
of mRNA expression levels of Wnt signaling components: Lrp6, Dvl2, Dvl3, Axin2 (Fig. 
5H). Then, we assayed the functionality of the Wnt/β-Catenin pathway. The SuperTOP 
Flash-Luciferase construct, bearing several binding sites for TCF/LEF, was activated by 2.5-
fold 48h after siAhr (Fig. 5I). To assess how AHR modifies β-Catenin levels in MSC80 cells, 
we assumed that AHR is able to interact with β-Catenin and stimulates its degradation as 
described in intestine cancer cells (20). Immunoprecipitation of AHR indicated protein-
protein interaction of β-Catenin and AHR in MSC80 cells (Fig. 5J). 
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 Consequently, we hypothesized that the knock-down of Ahr increases the recruitment 
of β-Catenin with TCF/LEF complex on the level of myelin genes promoters. We localized 
LEF/TCF-β-Catenin binding sites on P0 and PMP22 promoters (12) (Fig. 5K). ChIP assays 
with β-Catenin antibodies showed that Ahr silencing increased the recruitment of β-Catenin 
on P0 (Fig. 5L, loading control: Fig. S4B) and Pmp22 promoters (Fig. 5M, Fig. S4B). 
Moreover, the binding of β-Catenin was also enhanced after Ahr silencing on the level of a 
Wnt target gene, Axin2 (Fig. S4C). GAPDH was used as a negative control (Fig. S4D). 
Collectively, these data demonstrate that AHR exerts its effect on myelin genes through 
Wnt/β-Catenin pathway.  
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DISCUSSION 
We reveal that AHR plays a crucial role in myelination process of the nerve and is 
overexpressed in nerve tumors. In a series of NF1-associated nerve sheath tumors we 
demonstrated that AHR signaling pathway is activated. We further analyzed other genes 
linked to the AHR and involved in tryptophan metabolism that lead to the synthesis of 
kynurenine, an endogenous ligand of AHR (19, 21, 22). The expression of two genes 
participating to the first steps of tryptophan metabolism, namely IDO1 and TDO2, was 
significantly increased in plexiform neurofibromas and MPNSTs. IDO1 and TDO2 found to 
be remarkably increased in malignant form compared to the benign form of these tumors 
suggesting an increased AHR activity in the malignant transformation.  The enzyme IDO1 
mediates the first, rate-limiting, step in tryptophan metabolites to kynurenine, and is up-
regulated under an inflammatory microenvironment (23). Through generation of 
downstream metabolites, IDO1 enzyme activity may affect immunity, including specific 
immunomodulatory or cytotoxic functions (21). It has been reported that L-kynurenine 
activates AHR (19), which positively regulates IDO1 expression in immune cells such as 
dendritic cells. Our observation showing a progressive up-regulation of IDO1 and TDO2 in 
plexiform neurofibromas (3-fold and 5-fold), and a further stimulation in MPNSTs (50-fold 
and 25-fold) suggests that kynurenine synthesis leading to AHR activation may play a role 
in peripheral nerve sheath tumor progression to malignancy. 
In addition to the biallelic inactivation of the NF1 gene, supplemental genetic lesions are 
necessary for malignant progression of plexiform neurofibromas. Alterations of additional 
genes (CDKN2A/B, TP53, SUZ12, EED) were detected in MPNSTs (3 24),. We have 
previously shown that Wnt/β-Catenin pathway was dysregulated in MPNSTs (25), and the 
present study reveals that AHR pathway is also activated in these tumors. Furthermore, we 
have described an elevation of Wnt5a (25) and AHR expression in MPNST tumours. 
Conversely, the knock-down of AHR in MPNST cells inhibits Wnt5a expression (not 
shown). Therefore, our data suggest a possible link between AHR and Wnt/β-Catenin 
pathways in MPNST.  
 Consequently, we inhibited AHR in MPNST cell lines to alter their survival. Both 
AHR antagonists (CH-223191 or TMF) and siAHR induced apoptosis of two MPNST cell 
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lines: 90-8 and STS26T. Again, this observation highlights the importance of AHR in SC 
malignancy in addition to NF1. Furthermore, AHR inhibition could down-regulate IL1ß that 
was elevated in MPNST tumors. Previous results suggested that AHR activation coupled 
with inflammatory signals can lead to synergistic induction of IL6 expression in tumor cells 
(26). We revealed a significant increase of IL1ß, IL6, IL8, CXCL5, and CXCL6 mRNA levels 
in plexiform neurofibromas and MPNSTs. These results confirm previous in vitro findings 
showing that AHR activation may promote the induction of IL6, and IL8 (27, 28), ), and 
highlight the implication of  the AHR in the regulation of inflammation pathway (29).  
 Previous studies from our laboratory and other have shown that some signaling 
pathways that are involved in myelination process (Wnt/ β-Catenin, mTOR, ERK) ,ironically 
or unfortunately, are deregulated in MPNST (, , (30, 31), 32). Therefore, we then enquired 
about the endogenous role of AHR in normal Schwann cell physiology and peripheral nerve 
myelination. We revealed that AHR is expressed in SC and in the sciatic nerve. We then 
revealed that Ahr-/- mice present an alteration in locomotion. Additionally, electron 
microscopy analyses depicted thinner myelin sheaths. These data unveil the role of the AHR 
on SC myelinating functions. Prenatal exposure of TCDD in rats provoked a delay in 
oligodendrocyte differentiation and maturation (34). TCDD could also disrupt the functions 
of AHR to provoke neuropathies. In fact, rats intoxicated by TCDD showed severe defects 
in myelin structure of tibial and sciatic nerve and reduction in nerve conduction velocity (35, 
36). Our results not only reinforce the endogenous role of AHR in normal myelination 
process, but also the mechanism by which it regulates myelination.  
 P0 and PMP22 myelin proteins are essential for an adequate structure of myelin 
sheath. Indeed, their disregulation or mutation is deleterious for myelin sheath structure, 
leading to peripheral neuropathies. P0 expression was drastically down-regulated in 
MPNST, and the knockout of the AHR enhanced P0 expression in Schwann cells. We showed 
that AHR predicted binding motifs in P0 and PMP22 promoters did not recruit AHR. We 
postulated that action of AHR is possibly mediated by β-Catenin because we observed an 
increase of β-Catenin binding on TCF/LEF binding sites of P0 and Pmp22 promoters after 
Ahr knock-down. We also showed that the KO of Ahr in mice activated Wnt signaling in SC. 
AHR has a dual function in regulating gene expression as a ligand-activated transcription 
factor, and as an E3 ubiquitin ligase. Kawajiri et al., showed that AHR E3 ubiquitin activity 
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has a role in β-Catenin degradation pathway that is independent of the APC system in 
intestine (20). We assume that the inhibition of AHR may reduce the degradation of β-
Catenin, which is consistent with (i) the direct interaction that we have detected between 
AHR and β-Catenin proteins, and (ii) the β-Catenin increase observed after Ahr knock-down.  
 In conclusion, our findings unraveled that the AHR is involved in myelination 
process.  This pathway is over-expressed in nerve tumors, which could also serve along with 
Wnt/β- Catenin pathway, as new markers for this specific type of cancer. As the inhibition 
of AHR induced apoptosis of MPNST cells, we can propose that this approach is further 
translatable. For instance, using either nanoparticles ( (38) 39) or Adeno Associated Virus 
(AAV) (40) to deliver siAHR to induce apoptosis of these malignant cells could be suggested 
in adjuvant to existing chemotherapy with reduced doses. This approach can reduce the 
complications like chemotherapy-induced peripheral neuropathy (CIPN). So, our results 
indicate that AHR could represent a novel and a potential therapeutic target for this type of 
peripheral nerve sheath tumors that are poorly responsive to the existing chemotherapeutics.  
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MATERIALS AND METHODS 
Animals 
Ahr knock-out mice are a gift from Prof. Alvaro Puga (Cincinnati, USA). Ahr-/- mice and 
wild-type controls were maintained on a mixed strain background (C57BL/6j:RJ) and housed 
in a temperature-controlled room with a 12 hours light/dark cycle. All experiments were 
performed on age-matched male mice. Adults animals were fed ad libitum with water and 
Global-diet® 2016S from Harlan (Gannat, France). All aspects of animal care were approved 
by the Regional Ethic Committee (authorization CE2-04). 
Treadmill test: forced locomotion 
Adult males Ahr-/- (n=5) and control mice were acclimated to the testing room during 24 
hours before each test. The forced locomotion of the mice was investigated using a 
commercial motorized treadmill. The speed of the treadmill was controlled by a tachymeter. 
After habituation session (speed = 6cm/s), mice were tested at a speed of 10 cm/s and 16cm/s 
the next day. 
Rod test- Static paradigm 
 The same set of animals was subjected to both the treadmill test and rod test. The set up 
consisted of a rod of 9.5 mm diameter and 5 cm length. After a period of habituation, animals 
were securely placed on the rod. The ability of the animal to remain on the rod without falling 
was investigated for a maximum period of 100 seconds. 
Rod test- Dynamic paradigm 
Dark platform were setup at one end of the rod, where the mice were let for habituation for 
10 minutes. Mice were primed to walk from a start point along a bar (70 cm long, 9.5 mm 
diameter) fixed 30 cm above the bench. Once the mice had succeeded in reaching the final 
destination several times by priming procedure, the test was recorded in three trials. We 
calculated the speed, and the number of faults. 
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Rotarod Test: forced paradigm 
Balance and motor coordination was tested using a motorized rotarod LE8200 apparatus 
(Bioseb, France). Adult were placed mice on a rotating treadmill drum (3 cm diameter) and 
mice’s latency to fall during the first 5 minutes of the trial was noted. The average time of 
fall for each trial was measured. Fixed speed Rotarod at 14 rpm for five consecutive days for 
WT mice has been performed Ahr-/- mice (n=5).  
Transmission electron microscopy 
 Electron microscopy was done using fixed sciatic nerves following the protocol 
described previously (14). Electron microscopy images were used for calculating the g-ratio 
by ImageJ.  
Patients and Samples 
After clinical examination, the surgical removal of dermal neurofibromas was proposed in 
case of esthetical burden. Resection or removal of plexiform neurofibromas was described 
previously (25). 
Expression of genes involved in the AhR signaling pathway in patients’ samples 
RT-qPCR has been carried out as described previously(25). 
 
Immunohistochemistry  
Human samples 
Immunohistochemistry of patient samples has been carried out as described previously(41). 
Immunostaining of AHR (rabbit polyclonal antibody clone H211, Santa Cruz) was done at 3 
µg/ml after heat antigen retrieval in pH 6.0 citrate buffer. In all samples, we checked the 
absence of staining in intra-tumoral vessels and fibroblasts as internal negative controls.  
Mouse samples 
Sciatic nerves were dissected and immersed in 4% paraformaldehyde and embedded in OCT 
Sections (10 µm) were cut using Cryostat. P0 (Aves labs inc.) antibody, AHR antibody 
(Enzo). Then the samples were incubated at room temperature for 1h30 with the appropriate 
secondary antibody (Alexa Fluor 488 donkey anti-mouse, Cy3-conjugated AffiniPure 
Donkey anti-Rabbit and Cy3-conjugated Affinity Pure Donkey anti-Chicken). Nuclei were 
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stained with Hoechst 33342 (Pierce Biotechnology). Sections were imaged using a confocal 
microscope (LSM510; Carl Zeiss). 
Cell culture 
The mouse SC line (MSC80) was maintained in Dulbecco’s minimal essential medium 
(DMEM) supplemented with 10% decomplemented fetal calf serum (Hyclone-Perbio), 1% 
penicillin, 1% streptomycin (Gibco) and 1% Glutamine. All cultures were grown at 37°C in 
a humidified atmosphere of 5% CO2. 
The MPNST-derived cell lines STS26T and 90-8 were maintained in advanced RPMI-1640 
with 15% heat-inactivated FBS, 2.75‰ Bovine Pituitary Extract, 100U/ml penicillin, and 
100μg/ml streptomycin (Invitrogen).  
Plasmids and chemicals 
p1646 (Cyp1A1-luc) was graciously provided by Dr A. Puga (Cincinnati, USA). siRNAs 
directed against Ahr were purchased from Qiagen (Lafayette, CO). The Ahr was targeted by 
four siRNAs recognizing four different regions of Ahr transcript. TCDD was purchased from 
LGC standards, CH-22319 and 6, 2′, 4′-trimethoxyflavone (TMF) from Sigma. 
Transient transfections 
MSC80 cells (2.5 x 105 cells/well) were grown in 6-well plates, transfected using Effecten 
reagents according to manufactures instructions (Qiagen) and luciferase activity was 
determined using the enzymatic method described previously (42). The b-galactosidase 
activity was used to normalize the transfection efficiency. 
STS26T or 90-8 cells were transfected with either Non-Targetting siRNA (DHARMACON) 
or siAHR (DHARMACON) using RNAiMAX (Thermo fisher) according to the 
manufacturer’s instruction.  
Western Blot 
WB assay was performed using standard techniques. Primary antibodies against P0 (and 
PMP22 were purchased from Abcam and Sigma respectively, β-Catenin from BD 
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Transduction, Active β-Catenin from Millipore, α-tubulin) from Sigma, SOX2 from Abcam, 
and AHR  from Enzo life science (Biomol SA-210).  
qPCR for MSC80 
Total RNA from cultured MSC80 was extracted using TRIzol® Reagent (Invitrogen, France) 
according to manufacturer’s instruction. qPCR was done as described previously(14). All 
results were normalized to the 26S mRNA level and calculated using the ΔCt method. The 
primer sequences used in real time qPCR are listed in the primers table. 
Chromatin Immunoprecipitation 
MSC80 cells (107) fixed with 1% formaldehyde for 10 min. The cross linking was quenched 
with 0.125M glycine for 10 minutes. Fixed chromatin was then isolated and physically 
sheared by sonication to obtain DNA fragments of length of 300-600 base pairs. 
Immunoprecipitation is done using Protein A/G magnetic nanobeads (Dynabeads life 
technologies). The antibodies used in ChIP assays are: 5 µg of AHR-specific antibody 
(Biomol SA-210) 5 µg of β-Catenin (BD transduction # 610154), Histone H3 (Signaling 
#2650), 5 µg Rabbit IgG (Sigma I5006). RT-qPCRs were done as mentioned earlier with the 
primer pairs listed in primers’ table. Then the percentage of input has been calculated as 
mentioned in (43).  
Co-Immunoprecipitation  
MSC80 cell lysates were pre-cleared with protein-A (Dynabeads® life technologies) and 
then the total protein was measured with BioRad RCDC. The lysate has been treated with 
DNAse to digest the genomic DNA. 3 µg of AHR antibody (BD transduction) is used to 
enrich AHR in 100 μg of total protein by using protein A Dynabeads (Rabbit IgG is used as 
negative control). Finally, the enriched protein samples were blotted with usual standard WB 
techniques with β-Catenin antibody (Biomol SA-210). 
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Flow cytometry analysis  
STS26T or 90-8 cells cultured in 12-well plates were treated with AHR antagonists or 
DMSO. Cells undergoing apoptosis at the indicated time were identified using Annexin V-
FITC apoptosis detection kit (Abcam ab14085), following the manufacturer's instruction. 
BD FACSCanto™II was used. A total of 10000 events were recorded at a light scatter to 
exclude debris and aggregate with a flow rate of less than 200 cells/second for each assay. 
The compensations and the settings were adjusted according to the assay. Data were analyzed 
using FlowJo Software. 
Statistical analysis 
Unless otherwise specified, means of treatment groups were compared with one-way 
analysis of variance (ANOVA). When the ANOVA showed that there were significant 
differences between the groups, Tukey’s test was used to identify the sources of these 
differences. A p value of ≤ 0.05 was considered statistically significant. Two groups 
comparisons were performed by the Student test. As the mRNA levels did not fit a Gaussian 
distribution in human samples, (a) the mRNA levels in each subgroup of samples were 
expressed as their median values and ranges, rather than their mean values and coefficients 
of variation, and (b) comparison between the three types of nerve sheath tumors were 
assessed by using the non-parametric Kruskal Wallis H test. Differences were considered 
significant at confidence levels greater than 95% (p < 0.05). 
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Figure legends 
Table 1: AHR pathway is dysregulated in nerve tumors. A, Total RNA was isolated from 
patients having dermal neurfibromas (n=8), Plexiform Neurofibromas (n=16), and MPNST 
(n=14). RT-qPCR were performed using primers recognizing specifically the genes 
indicated. Table indicates median [range] mRNA levels. mRNA levels were normalized such 
that the median value of the dermal neurofibromas was 1. Kruskal Wallis H test was used to 
compare MPNSTs vs plexiform neurofibromas vs dermal neurofibromas.  
Table 2: AHR is predominantly expressed in Schwann cells compared to mast cells and 
endothelial cells. A, Total RNA was isolated from normal human tissues. Table indicates 
median [range] mRNA levels. mRNA amounts (calculated as described in Materials and 
Methods) were normalized by using the endogenous control TBP transcript. 
Figure 1: AHR nuclear staining is detected in MPNST tissues. Formalin fixed, paraffin 
embedded human MPNST samples were stained with Hematoxylin-eosin-saffron (HES) and 
AHR was revealed by a specific antibody. A strong nuclear AhR staining was detected in a 
proportion of tumor cells while intra-tumoral vessels (arrows) and fibroblasts in a fibrous 
septa (*) were not stained, taken as internal negative controls. Peroxidase technique, 
diaminobenzidine chromogen, haematoxylin counterstain. Scale bar 100 µm. 
Figure 2: AHR inhibition causes apoptosis in MPNST cell line. A- B, STS26T cells were 
treated with either AhR antagonists (CH-223191 or TMF) or DMSO (vehicle) during 48h 
(A) or 72h (B). Cells are stained with Annexin and PI to detect cell death by flow cytometry: 
living cell population (Annexin V-/PI-), apoptotic cells (Annexin V+/PI-), late apoptotic cells 
(Annexin V+/PI+) and dead cells (Annexin V-/PI+). Results represent the means +/- SEM of 
at least four independent experiments. *p<.05, **p<.01, by Bonferroni’s post hoc tests after 
one-way ANOVA when compared to DMSO. C, STS26T cell line was treated with either 
AHR antagonists (CH-223191 or TMF) or DMSO (vehicle). 48h later, total RNA was 
extracted and RT-qPCR was performed using primers recognizing CYP1A1 and TBP to 
normalize the results. They represent the means +/- SEM of at least five independent 
experiments. *p<.05, ***p<0.001 by Student’s t test when compared to DMSO. D, STS26T 
cells were transfected with either siAhR (10nM and 20nM) or NT; 72h after medium change, 
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cells were stained with Annexin and PI to detect cell death by flow cytometry: living cell 
population (Annexin V-/PI-), apoptotic cells (Annexin V+/PI-), late apoptotic cells (Annexin 
V+/PI+) and dead cells (Annexin V-/PI+). Results represent the means +/- SEM of at least 
four independent experiments. *p<.05, **p<.01, by Bonferroni’s post hoc tests after one-
way ANOVA when compared to control (NT). E, Human STS26T cell line was transfected 
with siAHR (20nM) or NT; 72h later, total RNA was extracted and RT-qPCR were performed 
using primers to amplify AHR, , CYP1A1, and CYP1B1. Results were normalized to the TBP 
mRNA level and represent the means +/- SEM of at least five independent experiments. 
*p<.05, ***p<0.001 by Bonferroni’s test when compared to control (NT). F, STS26T cells 
were reverse transfected with siAHR (20nM) or NT, or incubated with CH-223191 (50µM, 
72h), TMF (10µM, 72h) or DMSO. Total RNA was extracted and RT-qPCR experiments 
were performed using primers recognizing IL1ß and TBP to normalize. Results represent the 
means +/- SEM of at least five independent experiments. *p<.05, ***p<0.001 by Student’s 
t test when compared with control (NT). 
Figure 3: Ahr ablation modifies myelin structure and locomotor behavior in adult mice. 
A, Immunohistochemistry was performed on WT sciatic nerve to localize AhR (green) and 
P0 (red). The slides were imaged using confocal microscope. This experiment was repeated 
at least three times, and a typical experiment is presented here. Scale bar = 100 μm. B, 
Immunocytochemistry experiment was performed on MSC80 cells. AHR localization is 
highlighted in red; nuclei were stained with Hoechst (blue). This experiment was repeated at 
least three times, and a typical experiment is presented here. Scale bar = 10 μm. C, Western 
blot showing the expression of AhR in MSC80 cells and in sciatic nerve. D, Gait parameter: 
8 weeks-old WT and Ahr-/- mice were placed on a treadmill at the speed of 10 cm/s and 16 
cm/s. Stride time was measured. E, Rotarod test : 8 weeks-old WT and Ahr-/- mice were 
subjected to Rotarod test for five days. The time that mice could stay on the Rotarod was 
measured each day. At least 5 animals per group were tested.  *p<0.05, ** p<0.01 Tukey’s 
post hoc tests after one-way ANOVA when compared with control for each day of the 
experiment. F, Rod test: Eight weeks-old WT and Ahr-/- mice were placed on the rod to 
perform either static or dynamic rod tests. Representative pictures of the posture of the mice 
on the rod. The red arrowhead indicates right hind limb where Ahr-/- mouse slipped G, Static 
rod test: Measurement of the time that WT and Ahr-/- mice could stay without dropping from 
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the rod. The test was stopped when mice succeed to stay 100 seconds. H, Dynamic rod test. 
The average speed to cross the rod was measured (cm/s). I, The number of faults (slips) 
counted for either WT or Ahr-/-. At least 5 animals per group were tested. *p<0.05, **p<0.01, 
***p<0.001 by Student’s t test when Ahr-/- were compared to WT mice. J, Sciatic nerves 
were isolated from either WT or Ahr-/- mice (8-weeks old). Then, ultrathin (50 –90 nm) cross-
sections were prepared from Epon embedded nerves. Scale bar, 2µm. K, Myelin thickness 
was calculated by g-ratio determination and L, axonal perimeter was estimated using 
electronic microscopy pictures quantified by ImageJ software. At least five animals per 
genotype were used. M, g-ratios were plotted against axonal perimeter.  N, Adult male WT 
or Ahr-/- mice were sacrificed, and then their sciatic nerves were dissected (at least n=6 per 
group). Total proteins were extracted, and western blots were performed using antibodies 
against P0, PMP22, SOX2, KROX20, β-Catenin, Active β-Catenin and α-tubulin (loading 
control). Figures represent a typical experiment. Western blots were quantified using ImageJ 
software. Black horizontal line between the lanes in the gels signifies a crop was made. Error 
bars indicate SEM *p<0.05, **p<0.01, ***p<0.001 by Student’s t test when Ahr-/- were 
compared to control mice.  
 
Figure 4: The KO of Ahr alters myelin ultrastructure, myelin proteins and myelination 
regulators during development. A, sciatic nerves from P7,  P21 and 8 weeks-old mice were 
extracted and total protein was prepared. AHR, KROX20, β-catenin expression levels were 
determined by WB. a tubulin served as loading control. Figures represent a typical 
experiment. Ultrathin (50 –90 nm) cross-sections were prepared from epon embedded P7, 
and P21 sciatic nerves. B, Electron micrographs of P7 mice (scale bar = 2µm) C, Myelin 
thickness of P7 mice sciatic nerves was estimated by g-ratio determination using electron 
microscopy pictures quantified by Image J software. D, Axonal perimeter was measured by 
Image J software. E, The number of myelinated axons were counted in a given unit area. F, 
P7 male WT or Ahr-/- mice were sacrificed, and then their sciatic nerves were dissected (at 
least n=6 per group). Total proteins were extracted, and western blots were performed using 
antibodies against P0, PMP22, Sox2, Krox20, β-Catenin, Active β-Catenin and α-tubulin 
(loading control). Figures represent a typical experiment. G, Immunohistochemistry was 
performed on WT or Ahr-/- sciatic nerves (P7). The slides were analyzed with a confocal 
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microscope: Krox20 (red), P0 (green), DAPI (blue). This experiment was performed with at 
least 4 animals per each group, and a typical experiment was presented here. Scale bars = 50 
μm. The number of Krox20 positive cells and DAPI positive cells was counted by means of 
ImageJ. **p<0.01, by Student’s t-test compared to control (WT). H, Electron micrographs 
of P21 mice (sale bare = 2µm), I, g-ratio determination using electron microscopy pictures 
quantified by ImageJ software. J, Axonal perimeter was measured. K, The number of 
myelinated axons were counted in a given unit area. Error bars indicate SEM. ***p<0.001, 
by Student’s t test when Ahr-/- were compared to WT mice.  L, P21 male WT or Ahr-/- mice 
were sacrificed, and then their sciatic nerves were dissected (at least n=6 per group). Total 
proteins were extracted, and western blots were performed using antibodies against P0, 
PMP22, Sox2, Krox20, β-Catenin, Active β-Catenin and α-tubulin.Figures represent a 
typical experiment. Western blots were quantified using ImageJ. Error bars indicate SEM 
*p<0.05, **p<.001, ***p<0.001, by Student’s t test when Ahr-/- were compared to WT mice. 
 
Figure 5: AHR does not bind to myelin gene promoters in MSC80 cells but acts via Wnt/β-
Catenin pathway. MSC80 cells were transfected with a siRNA directed against Ahr (siAhr) 
or a non-targeting siRNA (NT).  A, Total mRNA was extracted and P0 and Pmp22 transcripts 
were quantified by RT-qPCR. All results were normalized to the 26S mRNA level. B, 
MSC80 cells were co-transfected with siAhr or NT and P0-luciferase or PMP22-luciferase 
constructs. Luciferase activity was assayed. Results represent the means +/- SEM of at least 
five independent experiments. *p<.05, ***p<0.001 by Student’s t test when compared with 
control (NT).  C. Putative binding sites of AHR located on the levels of P0 and PMP22 were 
identified by means of MatInspector software. MSC80 cells were incubated with vehicle 
(Nonane) or TCDD (100nM, 24h). Chromatin immunoprecipitation assays with antibodies 
against AHR or Mock IgG (non-relevant negative control) or Histone H3 (positive control) 
have been done. RT-qPCR was performed with primers recognizing AHR putative sites 
located on D, Cyp1A1 an AHR target gene; E, Pmp22; F, P0 genes. Results represent the 
means +/- SEM of at least four independent experiments. *p<.05, **p<.01, ***p<0.001 by 
Tukey’s post hoc tests after one-way ANOVA when compared with control. MSC80 cells 
were transfected with siRNA directed against Ahr (siAhr) or a non-targeting siRNA (NT) for 
48h. Proteins were extracted, and Western blots were performed using antibodies against G, 
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Total β-Catenin or active β-Catenin and α-tubulin as a loading control. Figures represent a 
typical experiment. Western blots quantifications were done using ImageJ software. H, Total 
RNA was extracted, and quantitative real-time PCR experiments were performed using 
primers recognizing Lrp6, Dvl2, Dvl3, Axin2. RT-PCR was normalized using 26S RNA. Data 
represent the mean+/-SEM of at least four independent experiments. I, MSC80 cells were 
transiently transfected SuperTOP Flash-luciferase (STF-Luciferase) and with either siAhr or 
NT. 48h later, luciferase activity was analyzed. Results represent the means +/- SEM of at 
least six independent experiments performed in duplicate. *p<0.05, **p<0.01, by Student’s 
t test. J, Co-immunoprecipitation assays were performed on MSC80 cells extracts using 
AhR, β -Catenin and IgG as a control. K, The binding sites for TCF/LEF- β-Catenin are 
localized on the promoter level for P0 and PMP22 as described by (12). MSC80 cells were 
transiently transfected with either siAhr or NT for 48h after, Chromatin immunoprecipitation 
assays with antibodies against β-Catenin or Mock IgG or Histone H3 have been done. 
Primers recognizing TCF/LEF/β-Catenin binding sites on the levels of P0 (L), Pmp22 (M) 
were used. Results represent the means +/- SEM of at four independent experiments. *p<.05, 
**p<.01, ***p<0.001 by Tukey’s post hoc tests after one-way ANOVA when compared with 
control.  
 
Figure S1: Representative dot plots of flow cytometry quantification. A, STS26T cells were 
treated either with AHR antagonists (CH (50µM) and TMF (10µM)) or Vehicle (DMSO) 
during 48h or 72h. Percentage of apoptotic cells (Annexin V+/PI-), dead cells (Annexin V-
/PI+), late apoptotic cells (Annexin V+/PI+) and living cells (Annexin V-/PI-) was analyzed 
by flow cytometry. Human MPNST cell line (STS26T) was reverse transfected with either 
siAHR or NT. B, Representative dot plots of STS26T cells silenced with siAHR. 
Figure S2: AHR inhibition causes apoptosis in MPNST cell line A, 90-8 cells were treated 
with either CH-223191 (50µM, 48h) or DMSO (vehicle). Total RNA was extracted and RT-
qPCR experiments were performed using primers recognizing CYP1A1 and CYP1B1. 
Results were normalized to the TBP mRNA level. They represent the means +/- SEM of at 
least five independent experiments. B-C 90.8 cells were treated with either CH-223191 
(50µM, 48h or 72h) or DMSO (vehicle). 48h or 72 after treatment, cells are stained with 
Annexin and PI to detect cell death by flow cytometry: living cell population (Annexin V-
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/PI-), apoptotic cells (Annexin V+/PI), late apoptotic cells (Annexin V+/PI+) and dead cells 
(Annexin V-/PI+). Results represent the means +/- SEM of at least four independent 
experiments. *p<.05, **p<.01, by Bonferroni’s post hoc tests after one-way ANOVA when 
compared to DMSO. D- E, MPNST cell line (90-8) was transfected with either NT or siAHR. 
72 hours post medium change Annexin and PI staining were done. Percentages of apoptotic 
cells (Annexin V+/PI-), dead cells (Annexin V-/PI+), late apoptotic cells (Annexin V+/PI+) 
and living cells (Annexin V-/PI-) were analyzed by flow cytometry. F, Human 90-8 cell line 
was transfected with siAhR (20nM) or NT; 72h later, total RNA was extracted and RT-qPCR 
were performed using primers to amplify AHR, , CYP1A1, and CYP1B1. Results were 
normalized to the TBP mRNA level and represent the means +/- SEM of at least five 
independent experiments. *p<.05, by Bonferroni’s test when compared to control (NT)..G, 
90-8 cells were treated with either AHR antagonists (CH-223191 50µM and TMF 10 µM) 
or DMSO (vehicle) and siAHR. Total RNA was extracted and RT-qPCR experiments were 
performed using primers recognizing IL1ß. Results were normalized to the TBP mRNA 
level. They represent the means +/- SEM of at least five independent experiments. *p<.05, 
***p<0.001 by Student’s t test when compared to control (NT). 
 
Figure S3:  Silencing efficiency of siAhr. MSC80 cells were transfected with non-targeting 
siRNA or a siRNA against Ahr (siAhr). A, Total RNA was extracted, and quantitative real-
time PCR experiments were performed using primers recognizing Ahr. The RT-PCR was 
normalized using 26S RNA. Results represent the mean +/-SEM of at least eight independent 
experiments. B, Proteins were extracted and Western blots were performed using antibodies 
against AHR and α-tubulin (normalization of the Western blots). Figures represent a typical 
experiment. Western blots quantification was done using Image J software. The data 
represent the mean+/-SEM of at least 4 independent experiments. C, MSC80 cells were 
transiently transfected CYP1A1-luc construct and with either siAhr or NT. 48h later, 
luciferase activity was analyzed. Results represent the means +/- SEM of at least 6 
independent experiments performed in duplicate. ***p<0.001 by Student’s t test compared 
to control (NT).  
Figure S4: Controls for ChIP assays. A, Western blot for ChIP assay where AHR antibody 
was used to precipitate AHR bound DNAs. MSC80 cells were treated with Nonane (vehicle) 
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or without TCDD for one hour and then fixed with PFA 4% to proceed with 
immunoprecipitation. B, Western blot for ChIP assay where β-Catenin antibody was used to 
precipitate β-Catenin - TCF/LEF bound DNAs. MSC80 cells were transfected with either 
non-targeting or siAhr for 48 hours and then fixed with PFA 4% to proceed with 
immunoprecipitation. C, Axin2 being a target gene of Wnt/β-Catenin served as a positive 
control. D, Gapdh served as a negative control.   
 
Figure S5: Uncropped western blots images of blots shown in main figures.   
 
active β-catenin to total β-catenin is increased 3.5-fold in Ahr−/−
mice, suggesting an activation of the Wnt/β-catenin pathway.
Ahr Is Involved in Myelination During Development. To determine
when these myelin abnormalities arose, we analyzed the ex-
pression pattern of AHR during the myelination process at P7,
P21, and in 8-wk-old (8WO) mice and compared it to the ex-
pression of positive modulators of the myelination process:
KROX20 and β-catenin. As depicted in Fig. 4A, AHR expression
was at the highest level at P7 and then decreased at later time
points to reach its lowest level in adult mice. KROX20 expres-
sion gradually increased during the myelination process to attain
the highest level at P21 and, as expected, dropped in adult ani-
mals. Finally, β-catenin increased at P21, and then its expression
was brought back to the same levels of P7 and at 8WO.
Taking account of this difference in AHR expression during
development, we analyzed the structure of myelin sheaths from
sciatic nerves of P7 mice (Fig. 4B). We observed a mild disor-
ganization of myelin sheaths in Ahr−/− mice without affecting the
g ratio (Fig. 4C). A moderate increase of the axonal perimeter
was detected in Ahr−/− mice (Fig. 4D). Nevertheless, Ahr−/− mice
displayed fewer myelinated axons (28.88 ± 1.18 for WT vs.
20.88 ± 1.23 for Ahr−/−; Fig. 4E). P0 (−50%) and PMP22
(−60%) protein expression was decreased in 7-d-old Ahr−/− mice
(Fig. 4F). To explore if myelin gene inhibition is due to a dys-
regulation in the expression of the major transcriptional regu-
lators of SC myelination, we quantified the expression of SOX2,
KROX20, total β-catenin, and active β-catenin. The knockout of
Ahr did not affect the expression of SOX2. However, we ob-
served a decreased KROX20 expression (−60%) that was con-
firmed by immunohistochemistry experiments. We observed a
25% reduction in the number of KROX20-positive cells in the
sciatic nerves as suggested by DAPI (Fig. 4G). Furthermore, WB
analyses showed that active β-catenin expression was diminished
by 30% in Ahr−/− nerves (Fig. 4F). As the amount of total β-catenin
was increased in Ahr−/− mice (+35%), we observed a decrease in
the ratio of active β-catenin to total β-catenin, suggesting an
impairment of the Wnt/β-catenin pathway at P7 when Ahr is
knocked out. At P21, electron microscopy images revealed that
myelin sheaths are affected by the deletion of Ahr (Fig. 4H). The
g ratio was decreased, designating thicker myelin sheaths around
the axons of Ahr−/− mice (Fig. 4I). The axonal perimeter was
reduced (Fig. 4J) while the numbers of myelinated were not af-
fected in Ahr−/− mice (Fig. 4K).
Fig. 1. (A and A′) AHR nuclear staining is detected in MPNST tissues.
Formalin-fixed, paraffin-embedded human MPNST samples were stained
with hematoxylin–eosin–saffron (HES), and AHR was revealed by a specific
antibody. (A) A strong nuclear AHR staining was detected in a proportion of
tumor cells, while intratumoral vessels (arrows) and fibroblasts in a fibrous
septa (*) were not stained, taken as internal negative controls. (A′) A per-
oxidase technique, diaminobenzidine chromogen, and hematoxylin coun-
terstain were employed. (Scale bar, 100 μm.)
Table 1. Median mRNA levels and ranges of 16 genes in dermal and PNFs and MPNSTs
Dermal neurofibromas,
n = 8 PNFs, n = 16 MPNSTs, n = 14
Genes Median Range Median Range Median Range P*
AHR pathway
AHR 1.00 0.13–11.59 6.84 0.01–71.01 8.98 0.57–63.28 P < 0.05
AHRR 1.00 0.56–8.44 0.39 0.13–1.60 0.49 0.07–1.80 P < 0.01
ARNT 1.00 0.76–3.38 2.12 0.65–5.78 1.71 0.49–7.62 NS
Trp metabolism
IDO1 1.00 0.04–10.75 2.98 0.11–41.54 49.38 1.59–681.64 P < 0.01
IDO2 1.00 0.21–6.74 0.60 0.07–5.06 0.65 0.01–18.21 NS
TDO2 1.00 0.05–101.38 7.21 0.25–77.62 24.77 0.86–2,931.70 P < 0.01
Myelin SCs
S100B 1.00 0.64–1.73 0.82 0.10–4.49 0.02 0.01–2.54 P < 0.01
MPZ 1.00 0.10–1.79 0.46 0.10–2.54 0.01 0.01–2.24 P < 0.01
Inflammation
IL-1B 1.00 0.26–4.09 19.44 0.01–809.67 6.15 2.66–644.12 P < 0.05
IL-6 1.00 0.50–1.95 19.86 0.18–247.60 25.67 3.06–32.04 P < 0.05
IL-8 1.00 0.07–3.15 8.98 0.01–648.32 13.65 0.19–269.89 P < 0.05
CXCL5 1.00 0.08–40.19 32.42 0.01–643.00 185.53 0.17–25,864.45 P < 0.01
CXCL6 1.00 0.01–5.66 10.86 2.28–1,642.39 24.33 4.60–862.02 P < 0.01
Xenobiotics metabolism
CYP1A1 1.00 0.01–1.88 2.16 0.10–18.85 1.50 0.40–4.11 NS
CYP1B1 1.00 0.49–5.78 1.01 0.12–9.07 0.69 0.11–4.42 NS
Proliferation
MKI67 1.00 0.30–2.82 1.39 0.88–4.77 31.43 13.6–82.9 P < 0.01
AHR pathway is dysregulated in nerve tumors. Total RNAwas isolated from patients having dermal neurfibromas (n = 8), PNFs (n = 16),
and MPNSTs (n = 14). qRT-PCR was performed using primers recognizing specifically the genes indicated. Table indicates median and
range mRNA levels. mRNA levels were normalized such that the median value of the dermal neurofibromas was 1. Kruskal Wallis H test
was used to compare MPNSTs vs. PNFs vs. dermal neurofibromas. NS, not significant. The bold values are statistically significant (P < 0.05).
*Kruskal Wallis H test: MPNSTs vs. PNFs vs. dermal neurofibromas.
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Figure 1. 
Cyp1A1 promoter. As expected, the AHR bound to the Cyp1A1
promoter (Fig. 5D). This binding was enhanced by twofold after
treatment with TCDD (100 nM, 1 h). However, we did not detect
AHR interaction with any of the putative binding sites identified
on Pmp22 (Fig. 5E) and P0 (Fig. 5F), even after the incubation of
MSC80 with TCDD (loading control, Fig. S4A). These data
showed that AHR does not seem to interact directly with myelin
gene promoters.
The other possible mechanism of action of AHR is the cross-
talk with another signaling pathway. We previously showed that
the activated Wnt/β-catenin pathway enhances the expression of
peripheral myelin genes (12). Furthermore, we demonstrated that
the knocking out of Ahr in mice altered β-catenin expression in the
sciatic nerve (Fig. 3N). Therefore, we addressed the question of
whether the action of AHR is mediated by the Wnt/β-catenin
pathway. After silencing Ahr in MSC80 cells, we observed a 50%
increase in the protein levels of active β-catenin and a 30% in-
crease of total β-catenin levels (Fig. 5G). Furthermore, to support
the hypothesis, knockdown of Ahr led to a significant stimulation
of mRNA expression levels of Wnt signaling components Lrp6,
Dvl2, Dvl3, and Axin2 (Fig. 5H). Then, we assayed the functionality
of the Wnt/β-catenin pathway. The SuperTOP Flash-Luciferase
construct, bearing several binding sites for T cell factor/lymphoid
enhancer factor (TCF/LEF), was activated by 2.5-fold 48 h after
siAHR (Fig. 5I). To assess how AHR modifies β-catenin levels in
MSC80 cells, we assumed that AHR is able to interact with
β-catenin and stimulate its degradation as described in intestine
cancer cells (20). Immunoprecipitation of AHR indicated protein–
protein interaction of β-catenin and AHR in MSC80 cells (Fig. 5J).
Consequently, we hypothesized that the knockdown of Ahr
increases the recruitment of β-catenin with TCF/LEF complex
on the level of myelin gene promoters. We localized LEF/TCF–
β-catenin binding sites on P0 and PMP22 promoters (12) (Fig.
5K). ChIP assays with β-catenin antibodies showed that Ahr si-
lencing increased the recruitment of β-catenin on P0 (Fig. 5L
and Fig. S4B, loading control) and Pmp22 promoters (Fig. 5M
and Fig. S4B). Moreover, the binding of β-catenin was also en-
hanced after Ahr silencing on the level of a Wnt target gene,
Axin2 (Fig. S4C). GAPDH was used as a negative control (Fig.
S4D). Collectively, these data demonstrate that AHR exerts its
effect on myelin genes through the Wnt/β-catenin pathway.
Discussion
We reveal that AHR plays a crucial role in the myelination
process of the nerve and is overexpressed in nerve tumors. We
demonstrated that the AHR signaling pathway is activated in a
series of NF1-associated nerve sheath tumors. We further ana-
lyzed other genes linked to the AHR and involved in tryptophan
metabolism that lead to the synthesis of kynurenine, an endog-
enous ligand of AHR (20–22). The expression of two genes
participating in the first steps of tryptophan metabolism, namely
IDO1 and TDO2, was significantly increased in PNFs and
MPNSTs. IDO1 and TDO2 were found to be remarkably in-
creased in malignant form compared with the benign form of
these tumors, suggesting an increased AHR activity in the ma-
lignant transformation. The enzyme IDO1 mediates the first,
rate-limiting, step in tryptophan metabolites to kynurenine and is
up-regulated under an inflammatory microenvironment (23).
Through generation of downstream metabolites, IDO1 enzyme
activity may affect immunity, including specific immunomodu-
latory or cytotoxic functions (21). It has been reported that
L-kynurenine activates AHR (19), which positively regulates IDO1
expression in immune cells, such as dendritic cells. Our observation
showing a progressive up-regulation of IDO1 and TDO2 in PNFs
(threefold and fivefold) and a further stimulation in MPNSTs (50-
fold and 25-fold) suggests that kynurenine synthesis leading to
AHR activation may play a role in peripheral nerve sheath tumor
progression to malignancy.
In addition to the biallelic inactivation of the NF1 gene, sup-
plemental genetic lesions are necessary for malignant progres-
sion of PNFs. Alterations of additional genes (CDKN2A/B,
TP53, SUZ12, EED) were detected in MPNSTs (3, 24). We have
previously shown that the Wnt/β-catenin pathway was dysregu-
lated in MPNSTs (15), and the present study reveals that the
AHR pathway is also activated in these tumors. Furthermore, we
have described an elevation of Wnt5a (15) and AHR expression
in MPNST tumors. Conversely, the knockdown of AHR in MPNST
cells inhibits Wnt5a expression (Fig. S2 H and I). Therefore, our
data suggest a possible link between AHR and Wnt/β-catenin
pathways in MPNSTs.
Consequently, we inhibited AHR in MPNST cell lines to alter
their survival. Both AHR antagonists (CH or TMF) and siAHR
induced apoptosis of two MPNST cell lines: 90–8 and STS26T.
Again, this observation highlights the importance of AHR in SC
malignancy in addition to NF1. Furthermore, AHR inhibition
could down-regulate IL-1β, which was elevated in MPNST tu-
mors. Previous results suggested that AHR activation coupled
with inflammatory signals can lead to synergistic induction of IL-
6 expression in tumor cells (25). We revealed a significant increase
of IL-1β, IL-6, IL-8, CXCL5, and CXCL6 mRNA levels in PNFs
and MPNSTs. These results confirm previous in vitro findings
showing that AHR activation may promote the induction of IL-
6 and IL-8 (26, 27) and highlight the implication of AHR in the
regulation of an inflammation pathway (28).
Previous studies from our laboratories and others have shown
that some signaling pathways that are involved in the myelination
process (Wnt/β-catenin, mTOR, ERK) are deregulated in
MPNST (12, 29, 30). Therefore, we inquired about the endog-
enous role of AHR in normal SC physiology and peripheral
nerve myelination. We revealed that AHR is expressed in SC
and in the sciatic nerve and that Ahr−/− mice present an alter-
ation in locomotion. Additionally, electron microscopy analyses
depicted thinner myelin sheaths. These data unveil the role of
AHR on SC myelinating functions. We performed electron mi-
croscopy analyses during the myelination process. They depicted
a disorganization of myelin sheaths depending on the develop-
mental stage. The first observation was that the myelin thickness
was not affected at an early stage of myelination (P7). However,
the number of myelinated axons was decreased in Ahr−/− mice,
suggesting a delay in myelination. Then, we observed thicker
myelin sheaths at P21, while adult animals had thinner myelin
sheaths around the axons. These observations could be compa-
rable to CMT1A patients (duplication of the PMP22 gene) who
Table 2. Relative mRNA expression of eight genes in different
human cells
Genes SCs Mast cells Endothelial cell
AHR pathway
AHR 426 11 6
AHRR 200 1,342 78
ARNT 1,105 492 479
Trp metabolism
IDO1 10 NE 2
IDO2 NE NE NE
TDO2 14 3 NE
Myelin markers
S100B 66,360 2 6
MPZ 24,336 4 5
AHR is predominantly expressed in SCs compared with mast cells and en-
dothelial cells. Total RNA was isolated from normal human tissues. The gene
mRNA levels (calculated as described in Materials and Methods) were based
on the amount of the target message relative to the endogenous control TBP
message, to normalize the starting amount and quality of total RNA. NE, not
expressed.
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active β-catenin to total β-catenin is increased 3.5-fold in Ahr−/−
mice, suggesting an activation of the Wnt/β-catenin pathway.
Ahr Is Involved in Myelination During Development. To determine
when these myelin abnormalities arose, we analyzed the ex-
pression pattern of AHR during the myelination process at P7,
P21, and in 8-wk-old (8WO) mice and compared it to the ex-
pression of positive modulators of the myelination process:
KROX20 and β-catenin. As depicted in Fig. 4A, AHR expression
was at the highest level at P7 and then decreased at later time
points to reach its lowest level in adult mice. KROX20 expres-
sion gradually incr sed during the myelination proc ss to attain
the highest level at P21 and, as expected, dropped in adult a i-
m ls. Finally, β-cat n n increased at P21, d then its expression
was brought back to the same levels of P7 and at 8WO.
Taking account of this differ nce in AHR exp ssion during
development, we analyzed the structure of my lin sheaths from
sciatic nerve of P7 mice (Fig. 4B). We observed a mild disor-
ganization of myelin sheaths in Ahr−/− mice without affecting the
g ratio (F g. 4C). A moderate incre se of the axonal perimeter
was detected in Ahr−/− mice (Fig. 4D). Neve theless, Ahr−/− mice
displayed f wer myelinated axons (28.88 ± 1.18 for WT vs.
20.88 ± 1.23 or Ahr−/−; Fig. 4E). P0 (−50%) and PMP22
(−60%) protein expression was decreased in 7-d-old Ah −/− mice
(Fig. 4F). To explore if myelin gene inhibition is due to a dys-
r gulation i the expression of the major transcripti nal regu-
lat rs of SC myelination, we quantified the expression of SOX2,
KROX20, total β-catenin, and active β-catenin. The knockout of
Ahr did not affect the expression of SOX2. However, we ob-
served a decreased KROX20 xpression (−60%) that was con-
firmed by immunohistochemistry experiments. We observed a
25% reduction in the number of KROX20-positive cells in the
sciatic nerves as suggested by DAPI (Fig. 4G). Furthermore, WB
analyses showed that active β-catenin expression was diminished
by 30% in Ahr−/− nerves (Fig. 4F). As the amount of total β-catenin
was increased in Ahr−/− mice (+35%), we observed a decrease in
the ratio of active β-catenin to total β-catenin, suggesting an
impairment of the Wnt/β-catenin pathway at P7 when Ahr is
knocked out. At P21, electron microscopy images revealed that
myelin sheaths are affected by the deletion of Ahr (Fig. 4H). The
g ratio was decreased, designating thicker myelin sheaths around
the axons of Ahr−/− mice (Fig. 4I). The axonal perimeter was
reduced (Fig. 4J) while the numbers of myelinated were not af-
fected in Ahr−/− mice (Fig. 4K).
Fig. 1. (A and A′) AHR nuclear staining is detected in MPNST tissues.
Formalin-fixed, paraffin-embedded human MPNST samples were stained
with ma oxylin–eosin–saffron (HES), and AHR was revealed by a specific
antibody. (A) A strong nuclear AHR staining was detected in a proportion of
tumor cells, while intratumoral vessels (arrows) and fibroblasts in a fibrous
septa (*) were not stained, taken as internal negative controls. (A′) A per-
oxidase technique, diaminobenzidine chromogen, and hematoxylin coun-
terstain were employed. (Scale bar, 100 μm.)
Table 1. Median mRNA levels and ranges of 16 genes in dermal and PNFs and MPNSTs
Dermal neurofibromas,
n = 8 PNFs, n = 16 MPNSTs, n = 14
Genes Median Range Median Range Median Range P*
AHR pathway
AHR 1.00 0.13–11.59 6.84 0.01–71.01 8.98 0.57–63.28 P < 0.05
AHRR 1.00 0.56–8.44 0.39 0.13–1.60 0.49 0.07–1.80 P < 0.01
ARNT 1.00 0.76–3.38 2.12 0.65–5.78 1.71 0.49–7.62 NS
Trp metabolism
IDO1 1.00 0.04–10.75 2.98 0.11–41.54 49.38 1.59–681.64 P < 0.01
IDO2 1.00 0.21–6.74 0.60 0.07–5.06 0.65 0.01–18.21 NS
TDO2 1.00 0.05–101.38 7.21 0.25–77.62 24.77 0.86–2,931.70 P < 0.01
Myelin SCs
S100B 1.00 0.64–1.73 0.82 0.10–4.49 0.02 0.01–2.54 P < 0.01
MPZ 1.00 0.10–1.79 0.46 0.10–2.54 0.01 0.01–2.24 P < 0.01
Inflammation
IL-1B 1.00 0.26–4.09 19.44 0.01–809.67 6.15 2.66–644.12 P < 0.05
IL-6 1.00 0.50–1.95 19.86 0.18–247.60 25.67 3.06–32.04 P < 0.05
IL-8 1.00 0.07–3.15 8.98 0.01–648.32 13.65 0.19–269.89 P < 0.05
CXCL5 1.00 0.08–40.19 32.42 0.01–643.00 185.53 0.17–25,864.45 P < 0.01
CXCL6 1.00 0.01–5.66 10.86 2.28–1,642.39 24.33 4.60–862.02 P < 0.01
Xenobiotics metabolism
CYP1A1 1.00 0.01–1.88 2.16 0.10–18.85 1.50 0.40–4.11 NS
CYP1B1 1.00 0.49–5.78 1.01 0.12–9.07 0.69 0.11–4.42 NS
Proliferation
MKI67 1.00 0.30–2.82 1.39 0.88–4.77 31.43 13.6–82.9 P < 0.01
AHR pathway is dysregulated in nerve tumors. Total RNAwas isolated from patients having dermal neurfibromas (n = 8), PNFs (n = 16),
and MPNSTs (n = 14). qRT-PCR was performed using primers recognizing specifically the genes indicated. Table indicates median and
range mRNA levels. mRNA levels were normalized such that the median value of the dermal neurofibromas was 1. Kruskal Wallis H test
was used to compare MPNSTs vs. PNFs vs. dermal neurofibromas. NS, not significant. The bold values are statistically significant (P < 0.05).
*Kruskal Wallis H test: MPNSTs vs. PNFs vs. dermal neurofibromas.
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Figure 2. 
At P21, P0 and PMP22 expression were stimulated by twofold
in Ahr−/− mice. SOX2 expression was still not affected, while the
expression of all of the positive regulators was activated in Ahr−/−
mice: KROX20 (+50%), total β-catenin (+60%), and active
β-catenin (+35%) (Fig. 4L). Altogether, our data point out a
crucial and differential role of Ahr during the myelination process
and highlight that Ahr knockout leads to defects in myelin sheaths.
AHR Regulates Myelin Gene Expression in SCs. We transfected
MSC80 cells with either nontargeting siRNA (NT) or siAhr.
First, the efficacy of the knockdown was evaluated by qRT-PCR
(Fig. S3A) and WB (Fig. S3B). In addition, we assessed the
functional efficacy of the siAhr on Cyp1A1—luciferase activity
that was reduced drastically (−80%) (Fig. S3C). The knock-
down of Ahr increased mRNA levels of P0 and Pmp22 by 50%
(Fig. 5A) and the promoter activity of P0 and Pmp22 (Fig. 5B).
Taken together, the silencing of Ahr in the SC line or its
knockout in mice led to a dysregulation of myelin gene expression.
Then, we examined the mechanism by which the AHR regu-
lates myelin gene expression. We identified by MatInspector
software four potential binding sites for AHR on the level of P0
promoter and one putative AHR binding site on the Pmp22
promoter (Fig. 5C). Therefore, we tested the AHR binding on
P0 and Pmp22 promoters by ChIP. As a positive control, we
assayed the binding of the AHR on the level of its target gene,
Fig. 2. AHR inhibition causes apoptosis in the MPNST cell line. (A and B) STS26T cells were treated with either AHR antagonists (CH or TMF) or DMSO (vehicle)
for 48 h (A) or 72 h (B). Cells are stained with Annexin and PI to detect cell death by flow cytometry: living cell population (Annexin V−/PI−), apoptotic cells
(Annexin V+/PI−), late apoptotic cells (Annexin V+/PI+), and dead cells (Annexin V−/PI+). Results represent the means ± SEM of at least four independent
experiments. *P < 0.05, **P < 0.01, by Bonferroni’s post hoc tests after one-way ANOVA compared with DMSO. (C) The STS26T cell line was treated with
either AHR antagonists (CH or TMF) or DMSO (vehicle). Forty-eight hours later, total RNA was extracted and qRT-PCR was performed using primers recog-
nizing CYP1A1 and TBP to normalize the results. They represent the means ± SEM of at least five independent experiments. *P < 0.05 by Student’s t test
compared with DMSO. (D) STS26T cells were transfected with either siAHR (10 nM and 20 nM) or NT; 72 h after medium change, cells were stained with
Annexin and PI to detect cell death by flow cytometry: living cell population (Annexin V−/PI−), apoptotic cells (Annexin V+/PI−), late apoptotic cells (Annexin
V+/PI+), and dead cells (Annexin V−/PI+). Results represent the means ± SEM of at least four independent experiments. *P < 0.05 by Bonferroni’s post hoc tests
after one-way ANOVA compared with control (NT). (E) STS26T cells were transfected with siAHR (20 nM) or NT; 72 h later, total RNA was extracted and qRT-
PCR was performed using primers to amplify AHR, CYP1A1, and CYP1B1. Results were normalized to the TBPmRNA level and represent the means ± SEM of at
least five independent experiments. *P < 0.05 by Student’s t test compared with control (NT). (F) STS26T cells were reverse-transfected with siAHR (20 nM) or
NT or incubated with CH (50 μM, 72 h), TMF (10 μM, 72 h), or DMSO. Total RNA was extracted and qRT-PCR experiments were performed using primers
recognizing IL-1β and TBP to normalize. Results represent the means ± SEM of at least five independent experiments. *P < 0.05 by Student’s t test compared
with control (NT).
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Figure 3. 
Fig. 3. Ahr ablation modifies myelin structure and locomotor behavior in adult mice. (A) Immunohistochemistry was performed on WT sciatic nerve to
localize AHR (green) and P0 (red). The slides were imaged using a confocal microscope. This experiment was repeated at least three times, and a typical
experiment is presented here. (Scale bar, 100 μm.) (B) An immunocytochemistry experiment was performed on MSC80 cells. AHR localization is highlighted in
red; nuclei were stained with Hoechst (blue). This experiment was repeated at least three times, and a typical experiment is presented here. (Scale bar, 10 μm.)
(C) WB showing the expression of AHR in MSC80 cells and in sciatic nerve. (D) In the gait parameter, 8-wk-old WT and Ahr−/−mice were placed on a treadmill
at the speed of 10 cm/s and 16 cm/s. Stride time was measured, ***P < 0.001 by Student’s t test when Ahr−/− were compared with control mice. (E) For the
rotarod test, 8-wk-old WT and Ahr−/−mice were subjected to the rotarod test for 5 d. The time that mice could stay on the rotarod was measured each day. At
least five animals per group were tested. *P < 0.05, **P < 0.01 using Mann–Whitney test compared with control for each day of the experiment. (F) For the
rod test, 8-wk-old WT and Ahr−/−mice were placed on the rod to perform either static or dynamic rod tests. Representative pictures of posture of the mice on
the rod are shown. The arrowhead indicates right hind limb where the Ahr−/−mouse slipped (G) For the static rod test, measurement of the time that WT and
Ahr−/− mice could stay without dropping from the rod. The test was stopped when mice succeeded in staying 100 s. (H) For the dynamic rod test, the average
speed to cross the rod was measured (cm/s). (I) The number of faults (slips) counted for either WT or Ahr−/−. At least five animals per group were tested. *P < 0.05,
**P < 0.01 by Student’s t test when Ahr−/−were compared with WT mice. (J) Sciatic nerves were isolated from eitherWT or Ahr−/−mice (8 wk old). Then, ultrathin
(50–90 nm) cross-sections were prepared from Epon embedded nerves. (Scale bar, 2 μm.) (K) Myelin thickness was calculated by g-ratio determination. (L) Axonal
perimeter was estimated using electronic microscopy pictures quantified by ImageJ software. At least five animals per genotype were used. (M) The g ratios were
plotted against the axonal perimeter. (N) Adult maleWT or Ahr−/− mice were killed, and then their sciatic nerves were dissected (at least n = 6 per group). Total
proteins were extracted, andWBs were performed using antibodies against P0, PMP22, SOX2, KROX20, β-catenin, active β-catenin, and α-tubulin (loading control).
Figures represent a typical experiment. WBs were quantified using ImageJ software. Black horizontal line between the lanes in the gels signifies a crop was made.
Error bars indicate SEM. *P < 0.05, **P < 0.01 by Student’s t test when Ahr−/− were compared with control mice.
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Figure 4. 
are hypermyelinated in early childhood and then, 1 y after, a
hypomyelination of some fibers is observed; it is caused by de-
myelination and remyelination cycles (31). The Ahr constitutive
invalidation also modified the perimeters of the axons, showing a
correlation between the formation of the myelin sheaths and
axonal development. However, we cannot exclude that could
also affect neuronal development directly. Prenatal exposure of
TCDD in rats provoked a delay in oligodendrocyte differentia-
tion and maturation (32). TCDD could also disrupt the functions
of AHR to provoke neuropathies. In fact, rats intoxicated by
TCDD showed severe defects in myelin structure of tibial and
sciatic nerve and reduction in nerve conduction velocity (33, 34).
Our results reinforce not only the endogenous role of AHR in a
normal myelination process but also the mechanism by which it
regulates myelination.
P0 and PMP22 myelin proteins are essential for an adequate
structure of myelin sheath. Indeed, their dysregulation or mutation
is deleterious for myelin sheath structure, leading to peripheral
neuropathies. P0 expression was drastically down-regulated in
MPNST, and the knockout of AHR enhanced P0 expression in SCs.
Fig. 4. The KO of Ahr alters myelin ultrastructure, myelin proteins, and myelination regulators during development. (A) Sciatic nerves from at least 4 mice of
age P7 and P21 were extracted and total protein was prepared. AHR, KROX20, and β-catenin expression levels were determined by WB. α-tubulin served as
the loading control. Figures represent a typical experiment. Ultrathin (50–90 nm) cross-sections were prepared from epon embedded P7, and P21 sciatic
nerves. (B) Electron micrographs of P7 mice. (Scale bar, 2 μm.) (C) Myelin thickness of P7 mice sciatic nerves was estimated by g-ratio determination using
electron microscopy pictures quantified by Image J software. (D) Axonal perimeter was measured by ImageJ software. (E) The number of myelinated axons
were counted in a given unit area. (F) P7 male WT or Ahr−/− mice were killed, and then their sciatic nerves were dissected (at least n = 6 per group). Total
proteins were extracted, and WBs were performed using antibodies against P0, PMP22, SOX2, KROX20, β-catenin, active β-catenin, and α-tubulin (loading
control). Figures represent a typical experiment. (G) Immunohistochemistry was performed onWT or Ahr−/− sciatic nerves (P7). The slides were analyzed with a
confocal microscope: KROX20 (red), P0 (green), and DAPI (blue). This experiment was performed with at least four animals per each group, and a typical
experiment was presented here. (Scale bars, 50 μm.) The number of KROX20-positive cells and DAPI-positive cells was counted by means of ImageJ. (H)
Electron micrographs of P21 mice. (Scale bar, 2 μm.) (I) The g-ratio determination using electron microscopy pictures quantified by ImageJ software. (J) Axonal
perimeter was measured. (K) The number of myelinated axons were counted in a given unit area. Error bars indicate SEM. (L) P21 male WT or Ahr−/− mice
were killed, and then their sciatic nerves were dissected (at least n = 6 per group). Total proteins were extracted, and WBs were performed using antibodies
against P0, PMP22, SOX2, KROX20, β-catenin, active β-catenin, and α-tubulin. Figures represent a typical experiment. WBs were quantified using ImageJ. Error
bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001, by Student’s t test when Ahr−/− were compared with WT mice.
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Figure 5. 
The knockout of Ahr severely altered P0 and PMP22 expression
during myelin development. At P7, when AHR expression is sup-
posed to reach its maximal expression, we observed an inhibition of
P0 and PMP22 expression, while starting from P21 until adulthood
the KO of Ahr increased the expression of myelin genes. Thus, it
appears that AHR differentially regulates P0 and PMP22 during de-
velopment. The dysregulation of the myelin gene could be attributed
to a modification of developmental markers that modulate P0 and
PMP22 expression. For example, at P7, the positive regulators of my-
elin gene expression (KROX20 and β-catenin) are down-regulated.
This undoubtedly provoked the inhibition of P0 and PMP22. At later
time points (P21 and adult), myelin genes are activated consequently
to the Ahr ablation. Concomitantly, KROX20 and β-catenin are
overexpressed and SOX2 (negative effector) is inhibited.
Fig. 5. AHR does not bind to myelin gene promoters in MSC80 cells but acts via the Wnt/β-catenin pathway. MSC80 cells were transfected with a siRNA
directed against Ahr (siAHR) or a NT siRNA (NT). (A) Total mRNA was extracted, and P0 and Pmp22 transcripts were quantified by qRT-PCR. All results were
normalized to the 26S mRNA level. (B) MSC80 cells were cotransfected with siAhR or NT and P0-luciferase or PMP22-luciferase constructs. Luciferase activity
was assayed. Results represent the means ± SEM of at least five independent experiments. ***P < 0.001 by Student’s t test compared with control (NT).
(C) Putative binding sites of AHR located on the levels of P0 and PMP22 were identified by means of MatInspector software. MSC80 cells were incubated with
vehicle (Nonane) or TCDD (100 μM, 24 h). ChIP assays with antibodies against AHR or Mock IgG (nonrelevant negative control) or Histone H3 (positive control)
were performed. qRT-PCR was performed with primers recognizing AHR putative sites located on (D) Cyp1A1, an AHR target gene; (E) Pmp22; and (F) P0
genes. Results represent the means ± SEM of at least four independent experiments. *P < 0.05 and ***P < 0.001 by Tukey’s post hoc tests after one-way
ANOVA compared with control. (G) MSC80 cells were transfected with siRNA directed against Ahr (siAhr) or a nontargeting siRNA (NT) for 48 h. Total proteins
were extracted, and WBs were performed using antibodies against total β-catenin or active β-catenin and α-tubulin as a loading control. Figures represent a
typical experiment. WB quantifications were done using ImageJ software. (H) Total RNA was extracted, and qRT-PCR experiments were performed using
primers recognizing Lrp6, Dvl2, Dvl3, and Axin2. RT-PCR was normalized using 26S RNA. Data represent the mean ± SEM of at least four independent ex-
periments. (I) MSC80 cells were transiently transfected with SuperTOP Flash-luciferase (STF-Luciferase) and with either siAHR or NT. Forty-eight hours later,
luciferase activity was analyzed. Results represent the means ± SEM of at least six independent experiments performed in duplicate. *P < 0.05, **P < 0.01, by
Student’s t test. (J) Coimmunoprecipitation assays were performed on MSC80 cell extracts using AHR, blotted for β-catenin by WB, and lgG was used as a
control. (K) The binding sites for TCF/LEF–β-catenin are localized on the promoter level for P0 and Pmp22 as described in ref. 12. MSC80 cells were transiently
transfected with either siAhr or NT for 48 h after; ChIP assays with antibodies against β-catenin or Mock IgG or Histone H3 were peformed. Primers rec-
ognizing TCF/LEF–β-catenin binding sites on the levels of P0 (L) and Pmp22 (M) were used. Results represent the means ± SEM of at four independent ex-
periments. *P < 0.05, ***P < 0.001 by Tukey’s post hoc tests after one-way ANOVA compared with control.
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Figure S1. 
Supporting Information
Shackleford et al. 10.1073/pnas.1715999115
Fig. S1. Representative dot plots of flow cytometry quantification. (A) STS26T cells were treated either with AHR antagonists [CH (50 μM) and TMF (10 μM)] or
vehicle (DMSO) for 48 h or 72 h. Percentage of apoptotic cells (Annexin V+/PI−), dead cells (Annexin V−/PI+), late apoptotic cells (Annexin V+/PI+), and living cells
(Annexin V−/PI−) was analyzed by flow cytometry. The human MPNST cell line (STS26T) was reverse-transfected with either siAHR or NT. (B) Representative dot
plots of STS26T cells silenced with siAHR.
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Figure S2. 
Fig. S2. AHR inhibition causes apoptosis in the MPNST cell line. (A) The 90–8 cells were treated with either CH (50 μM, 48 h) or DMSO (vehicle). Total RNA was
extracted and qRT-PCR experiments were performed using primers recognizing CYP1A1 and CYP1B1. Results were normalized to the TBP mRNA level. Results
represent the means ± SEM of at least four independent experiments. *P < 0.05 by Student’s t test. (B and C) The 90–8 cells were treated with either CH (50 μM,
48 h or 72 h) or DMSO (vehicle). At 48 h or 72 after treatment, cells were stained with Annexin and PI to detect cell death by flow cytometry: living cell
population (Annexin V−/PI−), apoptotic cells (Annexin V+/PI), late apoptotic cells (Annexin V+/PI+), and dead cells (Annexin V−/PI+). Results represent the
means ± SEM of at least four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, by Bonferroni’s post hoc tests after one-way ANOVA compared
Legend continued on following page
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Figure S3. 
with DMSO. (D and E) MPNST cell line (90–8) was transfected with either NT or siAHR. At 72 h post-medium change, Annexin and PI stainings were done.
Percentages of apoptotic cells (Annexin V+/PI−), dead cells (Annexin V−/PI+), late apoptotic cells (Annexin V+/PI+), and living cells (Annexin V−/PI−) were analyzed
by flow cytometry. *P < 0.05, **P < 0.01, ***P < 0.001, by Bonferroni’s post hoc tests after one-way ANOVA siAHR compared with NT. (F) The human 90–8 cell
line was transfected with siAHR (20 nM) or NT; 72 h later, total RNA was extracted, and qRT-PCR was performed using primers to amplify AHR, CYP1A1, and
CYP1B1. Results were normalized to the TBPmRNA level and represent the means ± SEM of at least five independent experiments. *P < 0.05, by Student’s t test
compared with control (NT). (G) The 90–8 cells were treated with either AHR antagonists (CH 50 μM and TMF 10 μM) or DMSO (vehicle) and siAHR. Total RNA
was extracted, and qRT-PCR experiments were performed using primers recognizing IL-1β. Results were normalized to the TBP mRNA level. They represent
the means ± SEM of at least five independent experiments. *P < 0.05, by Student’s t test compared with control (NT). (H) The 90–8 cells (I) STS26T were treated
with either NT or siAHR. Total RNA was extracted, and qRT-PCR experiments were performed using primers recognizing WNT5A. Results were normalized to
the TBP mRNA level. Results represent the means ± SEM of at least five independent experiments. *P < 0.05, ***P < 0.05, by Student’s t test compared with
control (NT).
Fig. S3. Silencing efficiency of siAhr. MSC80 cells were transfected with NT siRNA or an siRNA against Ahr (siAhr). (A) Total RNA was extracted, and qRT-PCR
experiments were performed using primers recognizing Ahr. The RT-PCR was normalized using 26S RNA. Results represent the mean ± SEM of at least eight
independent experiments. (B) Proteins were extracted and WBs were performed using antibodies against AHR and α-tubulin (normalization of the WBs).
Figures represent a typical experiment. WB quantification was done using ImageJ software. The data represent the mean ± SEM of at least four independent
experiments. (C) MSC80 cells were transiently transfected with CYP1A1-luc construct and with either siAhr or NT. Forty-eight hours later, luciferase activity was
analyzed. Results represent the means ± SEM of at least six independent experiments performed in duplicate. ***P < 0.001 by Student’s t test compared with
control (NT).
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Figure S4. 
Fig. S4. Controls for ChIP assays. (A) WB for ChIP assay where AHR antibody was used to precipitate AHR-bound DNAs. MSC80 cells were treated with Nonane
(vehicle) or without TCDD for 1 h and then fixed with 4% PFA to proceed with immunoprecipitation. (B) WB for ChIP assay where β-catenin antibody was used
to precipitate β-catenin–TCF/LEF-bound DNAs. MSC80 cells were transfected with either NT or siAhr for 48 h and then fixed with 4% PFA to proceed with
immunoprecipitation. (C) Axin2 being a target gene of Wnt/β-catenin served as a positive control. Student’s t test was used to compare siAhr with NT,
***P < 0.001. (D) Gapdh served as a negative control.
Shackleford et al. www.pnas.org/cgi/content/short/1715999115 4 of 6
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Figure S5 
Fig. S5. Uncropped WBs images of blots shown in the main figures. (A) Uncropped blots of 8WO mice (Fig. 3N). (B) Uncropped blots of P7 mice (Fig. 4E).
(C) Uncropped blots of P21 mice (Fig. 4J). (D) Uncropped blots of MSC80 (Fig. 5G). (E) Uncropped blots for Co-IP (Fig. 5J).
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Table S1. List of primers used for RT-qPCR
Primers Sequences
Ahr F: 5’GCCTTGGTCTTCTATGCTCT3’
R: 5’GCTTTGTGCTGGTTGTCAC3’
Dvl2 F: 5’GGCTTGTGTCGTCAGATACC3’
R: 5’TTTCATGGCTGCTGGATAC3’
Dvl3 F: 5′CCGATGAGGATGATTCCACC3′
R: 5′TGAGGCACTGCTCTGTTCTG3′
Axin2 F: 5’CCGATGAGGATGATTCCACC3’
R: 5’TGAGGCACTGCTCTGTTCTG3’
Lrp6 F: 5’ACAGACACTGGCACGGATCG3’
R: 5’GTTTGGCCAACCAAGGGAAG3’
26S F 5’-AGGAGAAACAACGGTCGTGCCAAAA-3’
R 5’-GCGCAAGCAGGTCTGAATCGTG-3’
RT-qPCR primers for β-catenin ChIP assays
P0 (8487/8471) F 5’-GGTCCTGAGTTCAAATCCC3-3’
R 5’-GAACCTTCATCTGTTGTTGG-3’
P0 (5487/5461) F 5’-TCTCTGGACAGAAAATGGAC-3’
R 5’-TTAACTCCTGGCAATCCTG-3’
Pmp22 (-107/-124) F 5’-GCTCCACCAGAGAACCTC-3’
R 5’-TGCCAATCAAACTCACCAGAC-3’
GAPDH-promoter F 5’-TCACCCTGCCCTCAATATCC-3’
R 5’-TGTGCCTTTCATTCCATCCA-3’
Axin2-TSS’ F 5’-AAGGCCCTGCTGTAAAAGGT-3
R 5’-GGGGGCTTTCTTTGAAGC-3’
Primers for clinical samples
AHR-U
AHR-L
AHRR
AHRR-L
TBP-U
TBP-L
F 5’-TAA CCC AGA CCA GAT TCC TCC AGA-3’
R 5’-CCC TTG GAA ATT CAT TGC CAG A-3’
F 5’-GGA AGG CTG CTG TTG GAG TCT CT-3’
R5’-TGG AAG CCC AGA TAG TCC ACG A-3’
F5’-TGC ACA GGA GCC AAG AGT GAA-3’
R 5’-CAC ATC ACA GCT CCC CAC CA-3’
Primers that are not listed here will be provided on request.
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